文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

富马酸替诺福韦艾拉酚胺在血浆中的种间稳定性差异。

Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.

作者信息

Parsons Teresa L, Gwenden Kevin N, Marzinke Mark A

机构信息

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

出版信息

Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00930-20.

DOI:10.1128/AAC.00930-20
PMID:32540983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7449208/
Abstract

Tenofovir (TFV) alafenamide fumarate (TAF) is an antiretroviral that has been evaluated in alternative drug delivery systems in several species. The stability of TAF was evaluated, and TAF was stable in dog-, sheep-, and macaque-spiked plasma. A negative bias was observed in TAF recovery in rabbit-spiked plasma; there was complete loss of TAF and corresponding overestimation of TFV in rodent-spiked plasma. These data highlight considerations when evaluating TAF and TFV concentrations in preclinical studies.

摘要

替诺福韦艾拉酚胺富马酸盐（TAF）是一种抗逆转录病毒药物，已在多个物种的替代给药系统中进行了评估。对TAF的稳定性进行了评估，结果显示TAF在添加了犬、羊和猕猴血浆的样本中稳定。在添加了兔血浆的样本中，TAF回收率出现负偏差；在添加了啮齿动物血浆的样本中，TAF完全损失，同时相应地高估了替诺福韦（TFV）。这些数据突出了在临床前研究中评估TAF和TFV浓度时需要考虑的因素。

相似文献

[1]
Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.

Antimicrob Agents Chemother. 2020-8-20

[2]
Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.

Pharm Res. 2023-9

[3]
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.

Infection. 2018-9-29

[4]
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).

Biochem Pharmacol. 2016-11-1

[5]
Tenofovir alafenamide fumarate.

Antivir Ther. 2022-4

[6]
[Tenofovir alafenamide fumarate - a new generation of tenofovir].

Klin Mikrobiol Infekc Lek. 2016-9

[7]
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.

Int J Infect Dis. 2020-1-25

[8]
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.

PLoS One. 2019-12-11

[9]
Population Pharmacokinetics of Tenofovir Alafenamide Fumarate and Its Metabolite Tenofovir in Healthy Chinese Volunteers.

Clin Pharmacol Drug Dev. 2024-2

[10]
An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.

Anal Biochem. 2020-3-15

引用本文的文献

[1]
Ultra-Long-Term Delivery of Hydrophilic Drugs Using Injectable Cross-Linked Depots.

bioRxiv. 2024-8-28

[2]
Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges.

Expert Opin Drug Deliv. 2022-10

[3]
Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.

Sci Rep. 2022-5-17

[4]
Bioequivalence Evaluation of Two Formulations of Tenofovir Alafenamide Tablets in Healthy Subjects Under Fasting and Fed Conditions.

Drug Des Devel Ther. 2021

[5]
Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis.

Front Pharmacol. 2020-11-25

本文引用的文献

[1]
Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats.

Int J Pharm. 2020-5-30

[2]
An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.

Anal Biochem. 2020-3-15

[3]
A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.

Antimicrob Agents Chemother. 2020-2-21

[4]
Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.

Open Forum Infect Dis. 2019-10-4

[5]
Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP).

Pharmaceutics. 2019-7-4

[6]
Simultaneous determination of tenofovir alafenamide and tenofovir in human plasma by LC-MS/MS and its application to pharmacokinetics study in clinic.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019-4-5

[7]
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

AIDS. 2019-7-15

[8]
Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.

J Control Release. 2018-8-6

[9]
Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.

J Pharm Biomed Anal. 2018-2-8

[10]
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.

AIDS Res Hum Retroviruses. 2018-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索